The Ethics Committee Relationship: What an IRB/IEC Must Approve Before Enrollment and the Four Duties That Keep Approval Alive

At a glance

• The ethics committee (IRB in the US, IEC elsewhere; same function) is not a one-time gatekeeper you petition once. It is a relationship you service for the life of the trial.
• No participant may be enrolled before you hold a documented, dated approval, and that approval covers specific documents: protocol, consent materials, recruitment ads, the Investigator’s Brochure, payment plans, and investigator qualifications.
• ICH E6(R3) puts four reciprocal duties on the investigator side: get approval before you start, deviate only with prior approval (except to remove an immediate hazard), report promptly, and supply continuing-review information.
• Composition and quorum are not formalities. An opinion issued by a committee that lacks the required members or a quorum is not a valid opinion.
• The EU CTR 536/2014 single-assessment model changed the old “one ethics committee per site” mental model: one application dossier, one reporting Member State, one binding decision per Member State.
• Where teams get caught: treating a deviation as something to explain afterward, running on a stale annual approval, and assuming a rubber-stamp committee produced a defensible opinion.

If you have ever watched a site’s first-subject-in slip by a month because the ethics committee asked one more question, you already understand the central point of this article: approval is not an event, it is a state you have to keep alive. The committee that protects your participants is also the committee that can suspend your trial. Treating it as a gated relationship, not a hurdle you clear once, is the difference between a clean inspection and a finding.

This guide maps that relationship for the practitioner who runs it day to day: the CRC assembling the submission, the CRA confirming approval before the first visit, the investigator deciding whether an event forces a trip back to the committee, and the clinical-ops coordinator tracking renewals. It is an operating model, not a bioethics lecture. The ethics-committee idea descends from the Declaration of Helsinki, but the working machinery is in the regulations, and that is where every claim below is grounded.

What an ethics committee actually is, and its single mandate

“IRB” and “IEC” name the same body. In US regulation it is the Institutional Review Board; ICH and most of the rest of the world say Independent Ethics Committee. The label changes; the function does not. Under ICH E6(R3) §1.2.1, the purpose of an IRB/IEC is to safeguard the rights, safety and well-being of all trial participants, with particular attention to trials that recruit vulnerable participants. Everything else the committee does is in service of that single mandate.

That mandate has teeth on both ends. The committee has authority not just to approve but to require modifications, to disapprove, and to suspend or terminate an approval it has already granted (ICH E6(R3) §1.2.3 lists those exact decision categories: approval, modifications required, disapproval, and termination or suspension of a prior approval). A committee that can only say yes is not protecting anyone; the power to stop a trial is the point.

Composition and quorum: why structure decides whether an opinion is valid

A favorable opinion is only as good as the body that issued it. Practitioners tend to skip this section because membership feels like the committee’s internal business. It is not. If composition or quorum fail, the opinion is not valid, and an invalid opinion does not protect your enrollment.

Composition and quorum: minimum conditions for a valid opinion

• ICH E6(R3) §1.3.1 recommends an IRB/IEC of a reasonable number of members who collectively can evaluate the science, medical aspects and ethics of the trial, and specifically: at least five members, at least one whose primary area of interest is not in medical sciences, and at least one who is independent of the institution/investigator site. Only members independent of the investigator and the sponsor should vote.
• ICH E6(R3) §1.3.3 requires decisions to be made at announced meetings at which at least a quorum, as set in the committee’s own procedures, is present.
• ICH E6(R3) §1.3.5 bars the investigator, site staff, or sponsor from participating in the committee’s decision-making or vote, even though they may supply information.
• US trials (FDA): 21 CFR §56.107 sets the same floor of at least five members of varying backgrounds, with at least one member whose primary concerns are scientific and at least one whose primary concerns are nonscientific (§56.107(c)), plus at least one member not otherwise affiliated with the institution (§56.107(d)). For the convened meeting, 21 CFR §56.108(c) requires a majority of members present, including at least one member whose primary concerns are nonscientific, and approval by a majority of those present.

The practitioner takeaway: when you receive an approval letter, the committee’s documented composition and the meeting minutes are part of what makes it defensible. ICH E6(R3) §1.3.1 also says a list of IRB/IEC members and their qualifications should be maintained, and §1.5.2 notes the committee may be asked to provide its procedures and membership lists. A “rubber-stamp” committee that cannot show its members and quorum has handed you a liability, not a clearance.

The pre-enrollment gate: what must be approved before any subject is enrolled

This is the hard line. ICH E6(R3) §1.4.6 specifies that no participant should be enrolled in a trial before the IRB/IEC issues its documented approval/favourable opinion. The investigator side restates it as a duty: under ICH E6(R3) §2.4.2, before initiating a trial the investigator/institution should have a documented and dated approval/favourable opinion from the IRB/IEC for the trial protocol, informed consent materials, participant recruitment procedures (such as advertisements), and any other trial-related information to be provided to participants. “Documented and dated” is doing work in that sentence: a verbal nod or a meeting that has not yet produced a letter is not approval.

What the committee actually reviews is broader than the protocol. ICH E6(R3) §1.2.2 lists the information the IRB/IEC should review where applicable, and that list is your submission-package checklist.

Submission-package checklist (from ICH E6(R3) §1.2.2)

• Protocol and amendments
• Informed consent material(s) and assent material(s), including the description of how consent and assent will be obtained
• Investigator’s Brochure or current scientific information (for example an SmPC, package leaflet, or basic product information brochure), including updates
• Other trial-related information to be provided to participants, including the media through which it is provided
• Advertisement for participant recruitment, if used, and information on the recruitment process
• Plans to compensate participants, if any
• Ongoing updates to safety information
• The investigator’s current curriculum vitae and/or other documentation of qualifications
• Any other documents the IRB/IEC needs to fulfil its responsibilities

Two items practitioners under-prepare. First, participant payment: ICH E6(R3) §1.2.8 requires the committee to review both the amount and the method of payment to assure neither creates coercion or undue influence, and notes payments should be timely, prorated, and not wholly contingent on completion. Reasonable reimbursement of travel and lodging is not coercive, but a large completion bonus invites a question. Second, the Investigator’s Brochure: under ICH E6(R3) §2.4.3 a current copy must accompany the submission, and if it is updated mid-trial the committee should receive the current version. A stale IB in the package is a common, avoidable stall.

The investigator’s four reciprocal duties under ICH E6(R3)

The listicles describe the committee’s duties and stop. The operating model that matters is the investigator’s side: four duties that keep an approval alive.

1. Obtain approval before starting. Covered above: ICH E6(R3) §2.4.2 and §1.4.6. No documented, dated approval, no enrollment.

2. Deviate only with prior approval, except to remove an immediate hazard. This is the one teams get backwards. ICH E6(R3) §1.4.7 specifies that no deviations from or changes to the protocol should be initiated without prior documented IRB/IEC approval of an appropriate amendment, except when necessary to eliminate immediate hazards to participants (or, where regulations allow, for purely logistical or administrative changes). The investigator-side mirror is ICH E6(R3) §2.5.4: the investigator should follow the protocol and deviate only where necessary to eliminate an immediate hazard, informing the sponsor promptly. The emergency carve-out is narrow and reactive; it is not a general license to change the protocol and explain later.

3. Report promptly. ICH E6(R3) §1.4.8 requires the investigator/institution to promptly report to the IRB/IEC: deviations made to eliminate immediate hazards; changes increasing risk to participants or significantly affecting the conduct of the trial; all suspected unexpected serious adverse reactions (SUSARs) per applicable regulatory requirements; and new information that may adversely affect participant safety or trial conduct. ICH E6(R3) §2.5.5 adds that where the investigator deviated to remove an immediate hazard, they should report the hazard, the change made, and any subsequent proposed amendment to the IRB/IEC. “Promptly” is the operative word; a report that arrives at the next annual review is not prompt.

4. Supply continuing-review information. The committee conducts continuing review under ICH E6(R3) §1.2.4 at intervals appropriate to the degree of risk to participants, and the investigator must feed it: ICH E6(R3) §2.4.5 requires documented summaries of trial status to be submitted to the IRB/IEC per local requirements or upon request. Note the framing in the ICH text, intervals “appropriate to the degree of risk,” and hold that thought; the US rule states it differently, and the difference is real (see Conflicts below).

When you go back to the committee: the re-engagement decision table

The recurring practitioner question is simple to ask and easy to get wrong: does this event force me back to the committee, and on what timeline? The table below is built strictly from the in-scope provisions.

Event	Re-engage the EC?	Gate / timeline
Protocol amendment (substantive change)	Yes, before implementing	Prior documented IRB/IEC approval of the amendment is required before the change is initiated (ICH E6(R3) §1.4.7). Minor changes may qualify for expedited review (ICH E6(R3) §1.4.5; for US trials, 21 CFR §56.110).
Urgent change to remove an immediate hazard	Act first, then report	The investigator may deviate without prior approval only to eliminate an immediate hazard (ICH E6(R3) §2.5.4), then must report the hazard, the change, and any proposed amendment to the IRB/IEC (ICH E6(R3) §2.5.5).
SUSAR / new safety information	Yes, promptly	Promptly report SUSARs and new information that may adversely affect participant safety or trial conduct (ICH E6(R3) §1.4.8(c)-(d)).
Protocol deviation made to remove a hazard	Yes, promptly	Promptly report deviations made to eliminate immediate hazards (ICH E6(R3) §1.4.8(a)).
Annual / periodic continuing review	Yes, on schedule	Continuing review at intervals appropriate to the degree of risk (ICH E6(R3) §1.2.4); for US trials, not less than once per year (21 CFR §56.109(f); 45 CFR §46.109(f)).
Premature termination or suspension of the trial	Yes, promptly	If the investigator terminates or suspends involvement without prior sponsor agreement, promptly inform the IRB/IEC with a detailed explanation (ICH E6(R3) §2.6.2).

If you take one row away, take the second: the immediate-hazard exception is the only time you act before the committee does, and it is reactive and reportable, not a planning tool.

EU CTR 536/2014 and the single-assessment model

EU readers carry a mental model from the old Directive era: one ethics committee opinion per site, negotiated locally. Regulation (EU) No 536/2014 reframed that. Under EU CTR Article 4, a clinical trial is subject to scientific and ethical review and must be authorised under the Regulation, with the ethical review performed by an ethics committee in accordance with the law of the Member State concerned. The Regulation deliberately leaves it to each Member State to decide which body performs the ethics review and how it slots into the timelines, but it pulls that review inside a single, coordinated process.

The structure is a Part I / Part II split. EU CTR Article 6 makes the reporting Member State responsible for Part I of the assessment report, the scientific and trial-wide aspects (benefit-risk, the investigational product, the Investigator’s Brochure), assessed jointly across all Member States concerned. EU CTR Article 7 keeps Part II national: each Member State concerned assesses, for its own territory, aspects such as informed consent, arrangements for compensating subjects, and recruitment. The output is one decision: EU CTR Article 8 requires each Member State concerned to notify the sponsor of a single decision (authorised, authorised subject to conditions, or refused), and a Member State must refuse authorisation where its ethics committee has issued a negative opinion that, under that State’s law, is valid for the entire Member State.

Independence and lay representation are written into the assessment itself. EU CTR Article 9 requires the persons assessing the application to be independent of the sponsor, the trial site, and the investigators, free of undue influence, and it mandates that at least one layperson participate in the assessment. That mirrors the ICH §1.3 independence and non-scientific-member requirements; the EU just locates them in the coordinated assessment rather than in a standalone site committee. The practical shift: you submit one dossier through the EU portal and manage one decision per Member State, not a patchwork of separate site-level ethics negotiations.

Where teams get it wrong

Deviation-first. The single most expensive mistake is treating a protocol change as something to implement and explain at the next review. ICH E6(R3) §1.4.7 and §2.5.4 are unambiguous: prior approval is the rule, the immediate-hazard carve-out is the only exception, and it is reactive. An unapproved deviation is not a paperwork lapse; it is a participant-protection failure that can trigger suspension.

Stale approval. Continuing review is a live obligation (ICH E6(R3) §1.2.4; 21 CFR §56.109(f); 45 CFR §46.109(f)). Running past a renewal date means you are enrolling and dosing under an approval that has lapsed. Track the renewal interval as a hard deadline, not an administrative nicety, and submit the status summary the committee needs (ICH E6(R3) §2.4.5) well ahead of it.

Quorum and independence failures. A favorable opinion from a committee that lacked the required members, lacked a quorum, or let a conflicted member vote is contestable (ICH E6(R3) §1.3.1, §1.3.3, §1.3.5; 21 CFR §56.107, §56.108(c)). You usually cannot audit the committee, but you can refuse to start until the documented, dated approval is in hand and insist the package was complete, because an incomplete submission is the most common reason an opinion gets reopened.

A note on scope: country-specific procedural mechanics (for example German or Indian ethics-committee rules) sit on top of these requirements and vary by jurisdiction; this article covers the ICH, US, and EU frameworks that the rest are built around. For the documents that travel with this relationship and the events that trigger re-engagement, see the sibling guides on informed consent under GCP, protocol deviation classification and timelines, and essential documents and the TMF, and the broader GCP roles and responsibilities overview.

Conflicts and tensions to surface, not reconcile

The in-scope regulations align on the core machinery, with one frequency difference worth stating plainly rather than smoothing over. ICH E6(R3) §1.2.4 sets continuing review at “intervals appropriate to the degree of risk to participants,” with no fixed floor. The US rules are more prescriptive: 21 CFR §56.109(f) and 45 CFR §46.109(f) both require continuing review at intervals appropriate to the degree of risk but not less than once per year. For a US trial you therefore carry a hard annual renewal regardless of how low-risk the study is, even though the ICH text alone would allow a risk-proportionate interval. Plan to the stricter applicable requirement; for US sites that means an annual review.

On composition, the frameworks reinforce rather than contradict each other: ICH E6(R3) §1.3.1, FDA 21 CFR §56.107, and EU CTR Article 9 independently require independence from the investigator/sponsor and the presence of a non-scientific or lay voice, so an opinion that violates one tends to violate all three.

Sources

• ICH E6(R3) Good Clinical Practice (version r3) — International Council for Harmonisation. https://www.ich.org/page/efficacy-guidelines
• Regulation (EU) No 536/2014 on Clinical Trials (version 2014) — European Parliament and Council. https://eur-lex.europa.eu/eli/reg/2014/536/oj
• 21 CFR Part 56 Institutional Review Boards (version 2024) — US Food and Drug Administration. https://www.govinfo.gov/content/pkg/CFR-2024-title21-vol1/pdf/CFR-2024-title21-vol1-part56.pdf
• 45 CFR 46 Protection of Human Subjects, Common Rule (version 2018) — US Department of Health and Human Services. https://www.govinfo.gov/content/pkg/CFR-2024-title45-vol1/pdf/CFR-2024-title45-vol1-part46.pdf